We report a 25-year-old @entity1 who developed @entity7995 and @entity1651 following primary @entity244 ( @entity244 ). @entity244 began with @entity10632 when she was 8 years old, and @entity16 subsequently developed at the age of 10 with @entity1269 . Based on clinical symptoms, serum positive for @entity6540 and @entity6016 antibodies and pathological findings of the salivary gland, we confirmed a diagnosis of primary @entity244 . Magnetic resonance imaging (MRI) revealed @entity75 in the brain and the spinal cord. These led diagnosis of @entity244 with central nervous system involvement (CNS- @entity244 ) and initiated @entity134 therapy. At the age of 25, the @entity1 developed left @entity227 due to retrobulbar @entity7995 , left lower quadrantic @entity1805 , numbness of the right upper limb, and @entity425 . Laboratory examinations showed that her serum was positive for @entity6540 and @entity6016 antibodies, and her cerebrospinal fluid had elevated levels of total protein and @entity2610 without pleocytosis. Her brain MRI revealed multiple T2-high-intensity lesions bilaterally in the frontal subcortical white matter and in the right temporo-parietal subcortical white matter. The lesions included a tumefactive lesion and an active lesion. Additionally, the spinal MRI revealed a severely atrophied spinal cord with T2-high-intensity lesions extending longitudinally and centromedullary in the spinal cord. These findings led us to examine the patient's serum for @entity3951 antibodies and the test confirmed that her serum was positive for the antibodies. After administering intravenous high-dose @entity1667 (1,000 mg/day for 3 days), her symptoms markedly improved with normalization of @entity2610 . However, her serum remained positive for @entity3951 antibodies. We think that the @entity1 's diagnosis belongs to the @entity1652 ( @entity1652 ) spectrum disorders associated with @entity792 . This is a rare case in that the initial presentation was @entity244 and occurred at a very young age.

[A 25-year-old @entity1 with primary Sj  gren syndrome who developed @entity7995 and @entity1651 associated with an anti- XXXX antibody].

@entity1 :: ('9606', 'Species') :: ['patient', 'woman'] @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual loss'] @entity2610 :: ('4155', 'Gene') :: ['myelin basic protein'] @entity6016 :: ('6741', 'Gene') :: ['SS-B'] @entity6540 :: ('6737', 'Gene') :: ['SS-A'] @entity1269 :: ('MESH:D010291', 'Disease') :: ['right hemiparesis'] @entity75 :: ('MESH:D001927', 'Disease') :: ['multiple lesions'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological involvement'] @entity1652 :: ('MESH:D009471', 'Disease') :: ['neuromyelitis optica', 'NMO'] @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness of both legs'] @entity7995 :: ('MESH:D009902', 'Disease') :: ['optic neuritis'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1805 :: ('MESH:D006423', 'Disease') :: ['hemianopia'] @entity244 :: ('MESH:D014899', 'Disease') :: ['SjS', "Sj  gren's syndrome"] @entity1651 :: ('MESH:D004679', 'Disease') :: ['encephalomyelitis'] @entity10632 :: ('MESH:D012859', 'Disease') :: ['Sicca syndrome'] @entity3951 :: ('361', 'Gene') :: ['anti-aquaporin (AQP) 4', 'AQP 4'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disorders']
@entity3951 :: (361,Gene) :: ['aquaporin 4']
